STOK | Ticker Profile - Titan Protect

STOK

Stoke Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$30.01

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.0B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-10.13

Based on estimated future earnings — lower means cheaper

Rev Growth

-96.1%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-45.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$40.00

+33% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 10 analysts covering this stock

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

https://www.stoketherapeutics.com

Country: United States Employees: 170 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.957

Good returns relative to risk taken

Kelly Fraction

0.0778

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.782

Acceptable balance between returns and drawdown risk

Annual Return

51.9%

Historical annualised return based on price data

Max Drawdown

-66.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.20

Moves slightly more than the broader market

52W High

$40.22

25% below the year high

52W Low

$9.34

221% above the year low

Avg Volume

710,759

Average daily shares traded — higher means easier to buy and sell

Short Ratio

25.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

21.6%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.86

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.87

Moderate leverage — manageable

Current Ratio

8.99

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

8.57

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-857.6%

Profit from core operations before interest and tax

Free Cash Flow

$-88,685,376

Negative — the business is spending more than it generates

Revenue (TTM)

$32M

Total revenue over the last 12 months

Net Income

$-169,767,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$60.00

Target Median

$40.00

Target Low

$35.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go